The success of molecularly targeted cancer therapy using tyrosine kinase inhibitors (TKIs) faces a number of difficult challenges. Foremost among these is the ability to identify subsets of different cancers that are uniquely sensitive to targeted agents, often identified by the presence of genetic markers implying """"""""dependence"""""""" or """"""""addiction"""""""" to the targeted pathway. Equally important to the longterm success of these therapies is understanding and circumventing acquired drug resistance, which is a key limitation to their clinical effectiveness. Acquired resistance to drugs targeting growth factor receptors differs from resistance to genotoxic cancer chemotherapy, and may include both specific mutations in targeted receptors, as well as more complex functional alterations in signaling networks. Here we will use non-small cell lung cancer (NSCLC) cell line models that appear to faithfully recapitulate key signaling dependence of cancers with activating mutations in the Epidermal Growth Factor Receptor (EGFR) gene, identifying a subset of lung cancers with extreme sensitivity to EGFR TKIs. We outline three aims that address the acquisition of resistance in tumors that were previously sensitive to these agents:
in Aim 1, we will generate cell line models for acquired resistance to """"""""second generation"""""""" irreversible inhibitors of EGFR, and use genetic, signaling and functional analyses to dissect the underlying mechanisms.
In Aim 2, we will use a high throughput shRNA screen of tyrosine kinases to identify candidate targets whose suppression may circumvent resistance to EGFR inhibitors.
In Aim 3, we will use lentiviral knockdown/reconstitution experiments to quantitate oncogene dependence of drug resistant cells, both on the initiating EGFR mutation and on associated signaling pathways that contribute to acquired drug resistance. Together, these aims will provide important insight into critical mechanisms that underlie the acquisition of resistance to novel inhibitors targeting growth factor receptors in human cancer.

Public Health Relevance

Understanding the mechanisms by which cancers that are sensitive to the new classes of targeted cancer therapies become resistant to these is critical to their eventual clinical success. Our approach is designed to dissect the molecular basis of resistance to these cancer drugs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Song, Min-Kyung H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Yazinski, Stephanie A; Comaills, Valentine; Buisson, Rémi et al. (2017) ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev 31:318-332
Kalinich, Mark; Bhan, Irun; Kwan, Tanya T et al. (2017) An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. Proc Natl Acad Sci U S A 114:1123-1128
Viswanathan, Vasanthi S; Ryan, Matthew J; Dhruv, Harshil D et al. (2017) Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547:453-457
Zheng, Yu; Miyamoto, David T; Wittner, Ben S et al. (2017) Expression of ?-globin by cancer cells promotes cell survival during blood-borne dissemination. Nat Commun 8:14344
Micalizzi, Douglas S; Maheswaran, Shyamala; Haber, Daniel A (2017) A conduit to metastasis: circulating tumor cell biology. Genes Dev 31:1827-1840
Micalizzi, Douglas S; Haber, Daniel A; Maheswaran, Shyamala (2017) Cancer metastasis through the prism of epithelial-to-mesenchymal transition in circulating tumor cells. Mol Oncol 11:770-780
Comaills, Valentine; Kabeche, Lilian; Morris, Robert et al. (2016) Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition. Cell Rep 17:2632-2647
Schrader, Kasmintan A; Stratton, Kelly L; Murali, Rajmohan et al. (2016) Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. J Clin Oncol 34:e61-7
Jordan, Nicole Vincent; Bardia, Aditya; Wittner, Ben S et al. (2016) HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature 537:102-106
Reátegui, Eduardo; Aceto, Nicola; Lim, Eugene J et al. (2015) Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Adv Mater 27:1593-9

Showing the most recent 10 out of 42 publications